VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology
Establishes Intellectual Property protection for proprietary RIOM clinical trial design
22nd December 2022 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has filed a country Patent to the UK Intellectual Property Office for ‘Method of Using Radiotherapy Parameters For Clinical Studies On Oral Mucositis’, supported by leading IP agency Gill Jennings & Every LLP.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“This country filing of intellectual property protection to our proprietary clinical trial methodology enables a priority claim and is the stepping stone for a global PCT filing. It represents an important element of our IP strategy as we progress a number of programmes aimed at transforming the standard of supportive care for a broad range of cancer patients worldwide.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.
